Đang chuẩn bị liên kết để tải về tài liệu:
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
PRECONNECT was an international, phase IIIb trial evaluating the safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer (mCRC). Patients with mCRC received FTD/TPI 35mg/m2 twice-daily on days 1–5 and 8–12 of each 28-day cycle for third- or later-line treatment. |